![]() ![]() “In summary, comparative data on trials of the new LAMA/ LABA FDC inhalers against one of the ICS/LABA combination inhalers (fluticasone plus salmeterol) are now available, and the results significantly favor the LAMA/ LABA inhalers in terms of efficacy (improvements in FEV1), patient-reported outcomes (TDI, mMRC), and quality of life measures (SGRQ),” concluded the study. Therefore, LAMA/LABA FDC is a more cost-effective option because of the reduction in long term adverse effects, including exacerbations, and the unpredictability of how much they can cost a COPD patient over time. O1.2.3 Long-acting bronchodilator combinations (LAMA/LABA) A number of LAMA/LABA fixed dose combinations in a single inhaler are available in Australia. 5 For patients with more severe COPD, GOLD. LAMA/LABA inhalers decrease the risk of pneumonia by 33% to 67%, according to the analysis. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend long-acting bronchodilators as the foundation for maintenance pharmacotherapy for COPD, with either long-acting 2 agonists (LABA) or long-acting muscarinic antagonists (LAMA) for improving lung function, relieving dyspnea, and reducing the frequency of exacerbations. “The new LAMA/LABA FDCs are now widely available and are a welcome addition to the options available for maintenance therapy in COPD.” “Given the significant adverse effects and increased incidence of pneumonia with long-term use of ICS, a favorable efficacy and safety profile of new LAMA/LABA FDCs versus ICS/LABA in COPD patients is very encouraging,” noted the researchers. Pnemonia rates, forced expiratory volume in 1 second (FEV 1), and other adverse events were also considered, and significant improvements were established in favor of the LAMA/LABA inhaler for COPD treatment. Annual exacerbation rates among participants treated with indacaterol/glycopyrronium, one type of LAMA/LABA inhaler, were lower than the fluticasone/salmeterol group in a study. LABA/LAMA was associated with a significantly lower risk of exacerbations and escalation to triple therapy compared to LABA/ICS, except in patients with. The analysis found significant decreases in exacerbation rates in the long duration trials with the dual bronchodilator. Long-term use of ICS has demonstrated increased incidence of pneumonia and other adverse effects. The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use.Ī new review published by Dove Press analyzes data from previous studies that draw comparisons between new therapies and ICS/LABA. As more long-term therapies for chronic obstructive pulmonary disease (COPD) are being developed, the results and efficacy of different therapies vary. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |